In 1998, CutisPharma was founded with a singular focus in mind: to address the needs of millions of patients who were unable to take capsules or tablets, and for whom no commercially available, FDA-approved therapy was available. Patients such as these, including children and the elderly, have traditionally needed a preparation compounded by a pharmacist, because there was no FDA-approved drug available to meet their needs.
However, drug compounding was adversely affected in many cases by a lack of standardized manufacturing and quality control processes. As recent events have highlighted, these quality shortcomings have resulted in concerns regarding the quality and safety of compounded drugs.
Our vision has been to provide high-quality, safe and accurate therapy to help pharmacists prepare drugs for those populations most in need for a better alternative to traditionally-compounded medications. CutisPharma pioneered the concept of unit-of-use prescription compounding kits. FI℞ST® Unit of Use Kits, as these products were known, provided an innovative alternative to traditional compounding, standardizing the dosing, and formulation, and assuring stability of a prescribed oral liquid therapy. With FI℞ST® ‘s convenient-to-dispense, single kit format, pharmacists could easily, safely, and accurately compound prescriptions of commonly-prescribed oral liquid therapies. Over the last 20 years, millions of patients have benefited from our products.
We have continued to push the frontiers of our vision. We are building upon our strong legacy in the compounding market and focusing our efforts to develop FDA-approved drugs to meet the needs of patients needing an oral liquid formulation. It is a simple extension of our long-standing vision to meet our patients’ unmet needs- allowing patients who previously had no FDA-approved alternative to now be able to have one.
On January 29th CutisPharma announced that the US Food and Drug Administration (FDA) has approved FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
We have a strong portfolio of drugs in development, and an incredibly talented, dedicated team that believes strongly in our mission to, benefit the lives of patients by bringing the best science and unrelenting commitment to quality into everything that we do. Every day, here at CutisPharma, we are transforming medicine through innovation. We’re glad you are here to learn more about who we are and what we do.
Azurity Pharmaceuticals™, Inc. was formerly known as CutisPharma®, Inc. Product packaging may reflect either name.
All product imagery is for representation purposes only - not actual labels.
© 2020 Azurity Pharmaceuticals™, Inc. All Rights Reserved.